AI
TARS icon

Atom Investors’s Tarsus Pharmaceuticals TARS Stock Holding History

Atom Investors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,494
Closed -$327K – 802
2025
Q3 		$327K Sell
5,494
-3,294
-37% -$162K 0.02% 427
2025
Q2 		$356K Buy
+8,788
New +$395K 0.03% 405

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Atom Investors's TARS Position: Q4 2025 in Review

Atom Investors sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 5,494 shares — an estimated $327K sold.

Atom Investors first reported a position in TARS in Q2 2025 and held it in 2 quarters. The position peaked at $356K in Q2 2025. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Atom Investors reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 5,494 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $327K.
  • Atom Investors first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Atom Investors's Tarsus Pharmaceuticals position peaked at $356K in Q2 2025.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.